Aarey Drugs & Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Aarey Drugs & Pharmaceuticals has a total shareholder equity of ₹1.4B and total debt of ₹386.5M, which brings its debt-to-equity ratio to 28.5%. Its total assets and total liabilities are ₹2.7B and ₹1.4B respectively. Aarey Drugs & Pharmaceuticals's EBIT is ₹44.0M making its interest coverage ratio -11.7. It has cash and short-term investments of ₹14.9M.
Key information
28.5%
Debt to equity ratio
₹386.50m
Debt
| Interest coverage ratio | -11.7x |
| Cash | ₹14.90m |
| Equity | ₹1.36b |
| Total liabilities | ₹1.39b |
| Total assets | ₹2.75b |
Recent financial health updates
Recent updates
Earnings Not Telling The Story For Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) After Shares Rise 46%
Aug 30
Aarey Drugs & Pharmaceuticals Limited's (NSE:AAREYDRUGS) Shares May Have Run Too Fast Too Soon
Jul 16Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Apr 15Aarey Drugs & Pharmaceuticals (NSE:AAREYDRUGS) Has A Pretty Healthy Balance Sheet
Mar 22What Aarey Drugs & Pharmaceuticals Limited's (NSE:AAREYDRUGS) P/E Is Not Telling You
Dec 30Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) Shares Fly 25% But Investors Aren't Buying For Growth
Dec 29Calculating The Fair Value Of Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS)
Aug 20Financial Position Analysis
Short Term Liabilities: AAREYDRUGS's short term assets (₹2.5B) exceed its short term liabilities (₹1.4B).
Long Term Liabilities: AAREYDRUGS's short term assets (₹2.5B) exceed its long term liabilities (₹4.9M).
Debt to Equity History and Analysis
Debt Level: AAREYDRUGS's net debt to equity ratio (27.4%) is considered satisfactory.
Reducing Debt: AAREYDRUGS's debt to equity ratio has increased from 19.5% to 28.5% over the past 5 years.
Debt Coverage: AAREYDRUGS's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: AAREYDRUGS earns more interest than it pays, so coverage of interest payments is not a concern.